Peter Allen

Peter Allen is a high-volume pancreatic surgeon and translational researcher advancing surgical outcomes and neoadjuvant therapy strategies for pancreatic cancer. His landmark clinical studies characterized long-term outcomes following pancreaticoduodenectomy for pancreatic cancer and defined pathological features predicting survival benefit from surgery. He has contributed to evidence-based IPMN management guidelines, characterizing worrisome features and high-risk stigmata that indicate increased malignancy risk requiring surgical intervention. His neoadjuvant chemotherapy research in borderline resectable and locally advanced PDAC has advanced the evidence for systemic therapy before surgery to improve resection rates and outcomes.